Natera, INC Form 4 insider transactions

Natera Inc. CEO and President Steven Leonard Chapman sold 3,848 shares of common stock on January 2, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Natera Co-Founder Jonathan Sheena sold 1,500 shares of common stock through pre-arranged trading plans on December 19, 2025.

Jonathan Sheena, Co-Founder and Director of Natera, Inc., reported the disposition of 4,130 shares of common stock, including a charitable contribution and sales under a pre-arranged trading plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, reported exercising stock options, selling shares to cover taxes, and making charitable contributions of common stock.

Natera Director Herm Rosenman sold approximately $11 million worth of common stock in multiple transactions on December 12, 2025, following the acquisition of 132 restricted stock units on October 31, 2025.

Jonathan Sheena, Co-Founder and Director of Natera, Inc., exercised stock options to acquire 4,436 shares of common stock.

Natera Inc. Director Rowan E. Chapman exercised stock options and subsequently sold a portion of the acquired common stock.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, exercised stock options for 6,902 shares of common stock at $19.68 per share.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,900 shares of common stock on December 1, 2025, under a pre-arranged 10b5-1 trading plan.

Natera Inc.'s CEO and President, Steven Leonard Chapman, sold 4,400 shares of common stock on December 1, 2025, through a pre-arranged 10b5-1 trading plan.

A director at Natera, Inc. executed pre-planned sales of 75,000 common shares totaling approximately $17.5 million through estate planning vehicles.

Natera Co-Founder and Director Jonathan Sheena sold 14,000 shares of Natera common stock for approximately $3.2 million through pre-arranged Rule 10b5-1 trading plans.

Natera Director Roy D. Baynes executed multiple stock option exercises and subsequent sales of common stock, reducing his direct beneficial ownership by 5,112 shares.

Natera, Inc. Co-Founder and Director Jonathan Sheena reported sales of 4,960 shares of common stock through pre-arranged Rule 10b5-1 trading plans.

Natera's Executive Chairman, Matthew Rabinowitz, sold 22,900 shares of common stock on November 4, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Natera Co-Founder Jonathan Sheena sold 4,000 shares of common stock for approximately $800,273.60 through a pre-arranged 10b5-1 trading plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock for approximately $596,000 under a pre-arranged 10b5-1 trading plan.

Natera Director Brinkley Ruth Williams received 97 fully vested Restricted Stock Units as quarterly board compensation.

Natera Director Gail Marcus reported the acquisition of 121 shares as compensation and the subsequent sale of 122 shares under a pre-arranged trading plan.

Natera, Inc. Director Rowan E Chapman acquired 128 shares of common stock through a fully vested RSU grant on October 31, 2025, in lieu of quarterly retainer fees.

Natera Director Roelof Botha received 149 shares of common stock as compensation for board service, increasing his direct beneficial ownership in the company.

Natera, Inc. Director Monica Bertagnolli acquired 93 fully vested Restricted Stock Units in lieu of quarterly retainer fees for board service.

Natera Director Roy Baynes received 93 fully vested Restricted Stock Units as compensation for board service, increasing his beneficial ownership to 18,359 shares.

Natera's CEO and President, Steven Leonard Chapman, exercised stock options and subsequently sold a significant number of shares on November 3, 2025, under a pre-arranged trading plan.

Natera's Executive Chairman, Matthew Rabinowitz, reported the sale of 17,100 shares of common stock for approximately $3.42 million, executed under a pre-arranged 10b5-1 trading plan.

Natera's CEO, Steven Chapman, sold 6,015 shares of common stock across two transactions in late October 2025 to cover tax withholding obligations related to RSU vesting.

Natera's Chief Financial Officer, Michael Burkes Brophy, sold 5,063 shares of common stock across several transactions in late October 2025, primarily for tax withholding.

Natera Director and Co-Founder Jonathan Sheena sold shares of common stock to cover tax obligations related to RSU vesting, as per a pre-arranged 10b5-1 plan.

Natera's Secretary and Chief Legal Officer, Daniel Rabinowitz, sold shares of common stock to cover tax withholding obligations related to RSU vesting under a pre-arranged 10b5-1 plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold approximately $423,000 worth of common stock to satisfy tax obligations from RSU vesting.